Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592087 | SCV000701384 | pathogenic | not provided | 2016-08-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002497244 | SCV002815992 | likely pathogenic | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002530963 | SCV003458043 | likely pathogenic | RYR1-related disorder | 2023-10-18 | criteria provided, single submitter | clinical testing | This variant results in the deletion of part of exon 58 of the RYR1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in RYR1 are known to be pathogenic (PMID: 23919265, 25960145, 28818389, 30611313). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This variant has not been reported in the literature in individuals affected with RYR1-related conditions. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |